Challenges and open issues in the management of acquired hemophilia A (AHA)

Webert, 2012, Acquired hemophilia A, Semin. Thromb. Hemost., 38, 735, 10.1055/s-0032-1326779 Chang, 2014, The diagnosis and classification of autoimmune coagulopathy: an updated review, Autoimmun. Rev., 13, 587, 10.1016/j.autrev.2014.01.032 Cugno, 2014, Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy, Autoimmun. Rev., 13, 40, 10.1016/j.autrev.2013.08.001 Sborov, 2012, Acquired hemophilia A: a current review of autoantibody disease, Clin. Adv. Hematol. Oncol., 10, 19 Franchini, 2013, Acquired haemophilia A: a 2013 update, Thromb. Haemost., 110, 1114, 10.1160/TH13-05-0363 Chai-Adisaksopha, 2014, Younger age at presentation of acquired haemophilia A in Asian countries: a single-centre study and systematic review, Haemophilia, 20, e205, 10.1111/hae.12383 Wootla, 2009, Factor VIII—hydrolyzing IgG in acquired and congenital hemophilia, FEBS Lett., 583, 2565, 10.1016/j.febslet.2009.07.009 Wootla, 2011, Proteolytic antibodies activate factor IX in patients with acquired hemophilia, Blood, 117, 2257, 10.1182/blood-2010-07-296103 Zeitler, 2013, Long term outcome of patients with acquired haemophilia—a monocentre interim analysis of 82 patients, Atheroscler. Suppl., 14, 223, 10.1016/j.atherosclerosissup.2012.10.033 Collins, 2012, Therapeutic challenges in acquired factor VIII deficiency, Hematol. Am. Soc. Hematol. Educ. Program., 369–374 Collins, 2007, Treatment of acquired hemophilia A, J. Thromb. Haemost., 5, 893, 10.1111/j.1538-7836.2007.02433.x Sørensen, 2005, Tailoring haemostatic treatment to patient requirements — an update on monitoring haemostatic response using thrombelastography, Haemophilia, 11, 1, 10.1111/j.1365-2516.2005.01156.x Ehrlich, 2002, Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events, Haemophilia, 8, 83, 10.1046/j.1365-2516.2002.00532.x Hedner, 2003, Potential role of recombinant factor VIIa as a hemostatic agent, Clin. Adv. Hematol. Oncol., 1, 112 Baudo, 2012, EACH2 registry contributors. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry, Blood, 120, 39, 10.1182/blood-2012-02-408930 Borg, 2013, Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry, Haemophilia, 19, 564, 10.1111/hae.12138 Ingerslev, 2011, Parallel use of by-passing agents in haemophilia with inhibitors: a critical review, Br. J. Haematol., 155, 256, 10.1111/j.1365-2141.2011.08854.x Huth-Kühne, 2009, International recommendations on the diagnosis and treatment of patients with acquired hemophilia A, Haematologica, 94, 566, 10.3324/haematol.2008.001743 Hay, 1997, The treatment of bleeding in acquired hemophilia a with recombinant factor VIIa: a multicenter study, J. Thromb. Haemost., 78, 1463, 10.1055/s-0038-1665434 Ma, 2011, Treatment of acquired haemophilia with recombinant factor VIIa (rFVIIa): an updated analysis from the hemophilia and thrombosis research society (HTRS) registry, J. Thromb. Haemost., 9, 476 Lentz, 2014, A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project, J. Blood Med., 13, 1, 10.2147/JBM.S55216 Sumner, 2007, Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal, Haemophilia, 200713, 451, 10.1111/j.1365-2516.2007.01474.x Di Capua, 2014, Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases, Blood Transfus., 19, 1 Sallah, 2004, Treatment of acquired haemophilia with factor eight inhibitor bypassing activity, Haemophilia, 10, 169, 10.1046/j.1365-2516.2003.00856.x Holme, 2005, Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies, Haemophilia, 11, 510, 10.1111/j.1365-2516.2005.01136.x Schneiderman, 2004, Sequential Therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors, Haemophilia, 10, 347, 10.1111/j.1365-2516.2004.00912.x Zanon, 2013, High dose of human plasma-derived as first-line therapy in patients affected by acquired haemophilia A and concomitant cardiovascular disease: four case reports and a literature review, Haemophilia, 19, e50, 10.1111/hae.12033 Barillari, 2013, PdFVIII/VWF may be an alternative treatment for old medical patient with acquired haemophilia A and systemic vascular disease?, Transfus. Apher. Sci., 48, 59, 10.1016/j.transci.2012.08.005 Zeitler, 2005, Treatment of acquired hemophilia by the Bonn–Malmo Protocol: documentation of an in vivo immunomodulating concept, Blood, 105, 2287, 10.1182/blood-2004-05-1811 ClinicalTrials Morrison, 1993, Use of porcine factor VIII in the treatment of patients with acquired hemophilia, Blood, 81, 1513, 10.1182/blood.V81.6.1513.1513 Nilsson, 1991, Current status of DDAVP formulations and their use, Excerpta Med., 943, 443 Collins, 2010, Advances in the understanding of acquired haemophilia A: implications for clinical practice, Br. J. Haematol., 148, 183, 10.1111/j.1365-2141.2009.07915.x Mudad, 1993, DDAVP in acquired hemophilia A: case report and review of the literature, Am. J. Hematol., 43, 295, 10.1002/ajh.2830430413 Holmström, 2012, Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A—a two-centre experience, Haemophilia, 18, 544, 10.1111/j.1365-2516.2012.02748.x Rivard, 2003, Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution, Haemophilia, 9, 711, 10.1046/j.1351-8216.2003.00814.x Delgado, 2003, Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors, Br. J. Haematol., 121, 21, 10.1046/j.1365-2141.2003.04162.x Collins, 2009, First line immunosuppressive treatment for acquired factor VIII antibodies: results of the European acquired haemophilia registry (EACH2), J. Thromb. Haemost., 7, 609 Schwartz, 1995, A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin, Blood, 86, 797, 10.1182/blood.V86.2.797.bloodjournal862797 Collins, 1870, UK Haemophilia Centre Doctors' Organisation. Acquired haemophilia A in the UK: a two year national surveillance study by UK Haemophilia Centre Doctors' Organisation, Blood, 109 Collins, 2012, Immunosuppression for acquired hemophilia A: results of the European Acquired Haemophilia (EACH) registry, Blood, 120, 47, 10.1182/blood-2012-02-409185 Dykes, 2001, Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitors: a 2-year review, Haemophilia, 7, 160, 10.1046/j.1365-2516.2001.00489.x Au, 2004, Successful treatment of acquired factor VIII inhibitor with cyclosporin, Haemophilia, 10, 98, 10.1046/j.1365-2516.2003.00837.x Pardos-Gea, 2006, Acquired haemophilia A: successful treatment with immunosuppression, methylprednisolone pulses and oral cyclosporin, Thromb. Haemost., 95, 735, 10.1160/TH04-12-0827 Brzoska, 2007, Immunoadsorption with single-use columns for the management of bleeding in acquired hemophilia A: a series of nine cases, J. Clin. Apher., 22, 233, 10.1002/jca.20139 Zeitler, 2009, Immunoadsorption in the treatment of acquired hemophilia, Atheroscler., 122, 10.1016/S1567-5688(09)71825-2 Boles, 2011, Single centre experience of rituximab as first-line immunosuppression for acquired haemophilia, J. Thromb. Haemost., 9, 1429, 10.1111/j.1538-7836.2011.04345.x Field, 2007, Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy, Haemophilia, 13, 46, 10.1111/j.1365-2516.2006.01342.x Franchini M, 2007, Rituximab in the treatment of adult acquired hemophilia A: a systematic review, Crit. Rev. Oncol. Hematol., 63, 47, 10.1016/j.critrevonc.2006.11.004 Nemes, 2000, New protocol for immune tolerance induction in acquired hemophilia, Haematologica, 85, 64 Smith, 1999, Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single Institution, Thromb. Haemost., 81, 35, 10.1055/s-0037-1614414 Butenas, 2006, Peptidomimetic inhibitors for activated protein C: implications for hemophilia management, J. Thromb. Haemost., 4, 2411, 10.1111/j.1538-7836.2006.02226.x Gal, 1998, Selection of a RNA aptamer that binds to human activated protein C and inhibits its protease function, Eur. J. Biochem., 252, 553, 10.1046/j.1432-1327.1998.2520553.x Hilden, 2012, Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model, Blood, 119, 5871, 10.1182/blood-2012-01-401620 Bunce, 2011, Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro, Blood, 117, 290, 10.1182/blood-2010-08-300756 von Drygalski, 2014, Improved hemostasis in hemophilia mice by means of an engineered FVa mutant, J. Thromb. Haemost., 12, 363, 10.1111/jth.12489 Milanov, 2012, Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice, Blood, 119, 602, 10.1182/blood-2011-05-353672 Muto, 2014, Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation, J. Thromb. Haemost., 12, 206, 10.1111/jth.12474